Casi Pharmaceuticals Stock Current Asset
| CASI Stock | USD 1.52 0.10 6.17% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess CASI Pharmaceuticals' long-term financial health and intrinsic value.
The current Non Current Assets Total is estimated to decrease to about 9.9 M. The current Total Current Assets is estimated to decrease to about 39.3 M. CASI | Current Asset | Build AI portfolio with CASI Stock |
CASI Pharmaceuticals Company Current Asset Analysis
CASI Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current CASI Pharmaceuticals Current Asset | 17.15 M |
Most of CASI Pharmaceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CASI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CASI Current Asset Historical Pattern
Today, most investors in CASI Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CASI Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CASI Pharmaceuticals current asset as a starting point in their analysis.
CASI Pharmaceuticals Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
CASI Total Assets
Total Assets |
|
In accordance with the recently published financial statements, CASI Pharmaceuticals has a Current Asset of 17.15 M. This is 99.2% lower than that of the Biotechnology sector and 98.38% lower than that of the Health Care industry. The current asset for all United States stocks is 99.82% higher than that of the company.
CASI Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CASI Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CASI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing CASI Pharmaceuticals by comparing valuation metrics of similar companies.CASI Pharmaceuticals is currently under evaluation in current asset category among its peers.
CASI Fundamentals
| Return On Equity | -10.94 | ||||
| Return On Asset | -0.51 | ||||
| Profit Margin | (1.29) % | ||||
| Operating Margin | (1.64) % | ||||
| Current Valuation | 29.81 M | ||||
| Shares Outstanding | 15.49 M | ||||
| Shares Owned By Insiders | 48.38 % | ||||
| Shares Owned By Institutions | 23.63 % | ||||
| Number Of Shares Shorted | 27.46 K | ||||
| Price To Earning | (16.46) X | ||||
| Price To Book | 11.21 X | ||||
| Price To Sales | 0.75 X | ||||
| Revenue | 28.54 M | ||||
| Gross Profit | 12.96 M | ||||
| EBITDA | (34.87 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 24.57 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 22.14 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | (0.52) X | ||||
| Cash Flow From Operations | (29.22 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (2.54) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 233 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 23.55 M | ||||
| Total Asset | 53.67 M | ||||
| Retained Earnings | (700.08 M) | ||||
| Working Capital | 3.12 M | ||||
| Current Asset | 17.15 M | ||||
| Current Liabilities | 3.51 M | ||||
| Net Asset | 53.67 M |
About CASI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CASI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CASI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CASI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out CASI Pharmaceuticals Piotroski F Score and CASI Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.54) | Revenue Per Share | Quarterly Revenue Growth 0.83 | Return On Assets | Return On Equity |
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.